IRIDEX Corporation (IRIX)
 NASDAQ: IRIX · Real-Time Price · USD
 1.060
 0.00 (0.00%)
  Oct 31, 2025, 2:20 PM EDT - Market open
IRIDEX Revenue
IRIDEX had revenue of $13.57M in the quarter ending June 28, 2025, with 7.44% growth. This brings the company's revenue in the last twelve months to $49.74M, up 0.09% year-over-year. In the year 2024, IRIDEX had annual revenue of $48.67M, down -6.17%.
Revenue (ttm) 
 $49.74M
Revenue Growth 
 +0.09%
P/S Ratio 
 0.36
Revenue / Employee 
 $534,882
Employees 
 93
Market Cap 
18.01M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 28, 2024 | 48.67M | -3.20M | -6.17% | 
| Dec 30, 2023 | 51.87M | -5.10M | -8.96% | 
| Dec 31, 2022 | 56.97M | 3.07M | 5.69% | 
| Jan 1, 2022 | 53.90M | 17.56M | 48.30% | 
| Jan 2, 2021 | 36.35M | -7.10M | -16.34% | 
| Dec 28, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 29, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Jan 2, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| UnitedHealth Group | 435.16B | 
| Johnson & Johnson | 92.15B | 
| Merck & Co. | 63.62B | 
| AbbVie | 58.33B | 
| AstraZeneca | 56.50B | 
| Novartis AG | 56.37B | 
| Eli Lilly and Company | 53.26B | 
| Novo Nordisk | 49.11B | 
IRIX News
- 2 days ago - Iridex to Report Third Quarter 2025 Financial Results on November 11, 2025 - GlobeNewsWire
- 7 weeks ago - Iridex Corporation Receives Formal Notification of Nasdaq Listing Compliance - GlobeNewsWire
- 2 months ago - IRIDEX Corporation (IRIX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Iridex Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 4 months ago - Iridex Announces First Patient Enrolled in an Independent Landmark Investigator-Led UK Study Evaluating MicroPulse® Technology as an Adjunct to anti-VEGF Therapy for Diabetic Macular Edema - GlobeNewsWire
- 6 months ago - IRIDEX Corporation, Inc. (IRIX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 6 months ago - Iridex Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 6 months ago - IRIDEX Changes Course - Seeking Alpha